Immutep Limited (IMMP)

NASDAQ: IMMP · IEX Real-Time Price · USD
2.28
+0.05 (2.24%)
At close: Aug 8, 2022 3:54 PM
2.26
-0.02 (-0.88%)
After-hours: Aug 8, 2022 4:00 PM EDT
2.24%
Market Cap 197.51M
Revenue (ttm) 3.26M
Net Income (ttm) -18.81M
Shares Out 86.63M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,135
Open 2.15
Previous Close 2.23
Day's Range 2.15 - 2.30
52-Week Range 1.85 - 5.00
Beta 1.90
Analysts Buy
Price Target 7.93 (+247.8%)
Earnings Date Sep 7, 2022

About IMMP

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSC... [Read more...]

Industry Biotechnology
CEO Marc Voigt
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol IMMP
Full Company Profile

Financial Performance

In 2021, Immutep's revenue was 3.97 million, a decrease of -75.95% compared to the previous year's 16.50 million. Losses were -29.90 million, 122.0% more than in 2020.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for IMMP stock is "Buy." The 12-month stock price forecast is 7.93, which is an increase of 247.81% from the latest price.

Price Target
$7.93
(247.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line ...

SYDNEY, AUSTRALIA, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatment...

Immutep Quarterly Activities Report

SYDNEY, AUSTRALIA, July 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited  (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatmen...

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer a...

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatment...

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

SYDNEY, AUSTRALIA, June 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

SYDNEY, AUSTRALIA, May 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments...

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limi t ed (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatmen...

Immutep Presents New and Significant Data from the AIPAC Study

SYDNEY, AUSTRALIA, May 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments...

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited  (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatme...

Immutep's Efti in Combination with MSD's Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd...

SYDNEY, AUSTRALIA, March 30, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatme...

Immutep Announces Publication of TACTI-002 Abstract at ESMO's European Lung Cancer Congress 2022

SYDNEY, AUSTRALIA, March 24, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatme...

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO...

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its ...

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody m...

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast ...

SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Fo...

Immutep to Present at Healthcare Investor Conferences

SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immutep Limited  (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022

SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO's Europe...

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway ...

SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep to Present at February Investor Conferences

SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatme...

Immutep Advances IMP761 Manufacturing

SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

SYDNEY, AUSTRALIA, Dec. 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

SYDNEY, AUSTRALIA, Nov. 19, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Path...

SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Efti...

SYDNEY, AUSTRALIA, Nov. 15, 2021 (GLOBE NEWSWIRE) --   Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatme...